One Year Drug Treatment in First-Episode Schizophrenia

• Status: Completed
• Trial end date: 2005-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Prospective, randomized, double-blind, multi-center study on 1 year course and treatment outcome under low-dose typical (haloperidol) vs. atypical neuroleptics (risperidone) in first-episode schizophrenia.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Heinrich-Heine University, Duesseldorf
• Collaborators: German Federal Ministry of Education and Research; German Research Network On Schizophrenia; Humboldt-Universität zu Berlin; Janssen-Cilag Ltd.; Mainz University; Martin-Luther-Universität Halle-Wittenberg; RWTH Aachen University; Universität Duisburg-Essen; University Hospital Tuebingen; University of Bonn; University of Cologne; University of Göttingen; University of Jena; University of Mannheim; University of München; University of Wuerzburg
• Treatments: Haloperidol; Haloperidol decanoate; Risperidone

Criteria

Inclusion Criteria:

• After the acute treatment of the first-episode in schizophrenia (according ICD-10 F20)

• Age between 18 and 55

• Informed consent

Exclusion Criteria:

• Residence outside of the catchment area

• Legal reasons

• Insufficient knowledge of the German language

• Substance abuse or addiction

• Pregnancy

• Serious physical illness

• Organic brain disease

• Contraindication to neuroleptic treatment